Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12–13
HOS-108863 · Präparat HOS-093083
12
CYP3A4 inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Dronedarone Amiodarone, Dronedarone: Concomitant administration of
Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious
adverse reactions may be
increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if
inhibition by lopinavir/ritonavir. available, is recommended in case
The increased digoxin level may of co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra
in patients taking digoxin as the
acute inhibitory effect of ritonavir
on P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already
taking Kaletra is likely to result in
lower than expected increases of
digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine Quinidine: therapeutic drug concentration
Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of
may lead to a decreased exposure virological response.
of lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) clarithromycin (HOS-084517) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 2a6dc58dcb1aed961671098b7774afc6ab5284838d7c3becb73533d81f884e22 · Zeichen 9077–14069 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-109006 · Präparat HOS-093083
49
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of arrhythmias
or other serious adverse reactions
may be increased.
Digoxin Digoxin: Caution is warranted and therapeutic
Plasma concentrations may be drug monitoring of digoxin
increased due to P-glycoprotein concentrations, if available, is
inhibition by lopinavir/ritonavir. recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should be
induction develops. used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on P-gp
is expected to significantly increase
digoxin levels. Initiation of digoxin
in patients already taking Kaletra is
likely to result in lower than expected
increases of digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and therapeutic
Lidocaine, and Quinidine: drug concentration monitoring is
Quinidine Concentrations may be increased recommended when available.
when co-administered with
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4). Caution
lopinavir/ritonavir. should be exercised in administering
clarithromycin with Kaletra to
patients with impaired hepatic or
renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the abemaciclib
SmPC for dosage adjustment
recommendations. Monitor for
ADRs related to abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of virological
may lead to a decreased exposure response.
of lopinavir/ritonavir. In addition, co-administration of
apalutamide and Kaletra may lead to
Serum concentrations of serious adverse events including
apalutamide may be increased due seizure due to higher apalutamide
to CYP3A inhibition by levels. Concomitant use of Kaletra
lopinavir/ritonavir. with apalutamide is not
recommended.
Afatinib Afatinib: Caution should be exercised in
AUC: ↑ administering afatinib with Kaletra.
(Ritonavir 200 mg twice Cmax: ↑ Refer to the afatinib SmPC for
daily)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) afatinib (HOS-086207) clarithromycin (HOS-084517) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage e2bfc1f119ab72d4142e3587fc0d81da448b5ce69a5003d6154afba7723f33c1 · Zeichen 9850–14882 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 84–85
HOS-109080 · Präparat HOS-093083
84
Fentanyl Fentanyl: Careful monitoring of adverse
Increased risk of side-effects effects (notably respiratory
(respiratory depression, sedation) depression but also sedation) is
due to higher plasma recommended when fentanyl is
concentrations because of concomitantly administered with
CYP3A4 inhibition by Kaletra.
lopinavir/ritonavir.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious adverse
reactions may be increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if available,
inhibition by lopinavir/ritonavir. is recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on
P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already taking
Kaletra is likely to result in lower
than expected increases of digoxin
concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine: therapeutic drug concentration
Quinidine Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) clarithromycin (HOS-084517) fentanyl (HOS-086196) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 441e910c1e6908f1a8725254649dcb0f97fdc57cf122c18523aa47225be733b2 · Zeichen 9035–13902 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-109443 · Präparat HOS-093201
10
Antiarrhythmics
Digoxin (0.25 mg QD) Digoxin Cmax ↔ No dose adjustment
[P-gp substrate] Digoxin AUC ↔
Quinidine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of quinidine 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Antibacterials
Flucloxacillin Significantly decreased plasma If concomitant administration of
[CYP450 inducer] voriconazole concentrations have voriconazole with flucloxacillin
been reported. cannot be avoided, monitor for
potential loss of voriconazole
effectiveness (e.g., by therapeutic
drug monitoring); increasing the
dose of voriconazole may be
needed.
Macrolide antibiotics No dose adjustment
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 7a8effc9a992647295e4846d1245734c400d850ebf1025fae94741d36bf5f346 · Zeichen 3549–4872 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 42
HOS-109534 · Präparat HOS-093201
Medicinal product Interaction Recommendations concerning
geometric mean changes (%) coadministration
Antacids
Cimetidine (400 mg BID) Voriconazole Cmax 18% No dose adjustment
[non-specific CYP450 inhibitor Voriconazole AUC 23%
and increases gastric pH]
Omeprazole (40 mg QD)* Omeprazole Cmax 116% No dose adjustment of
[CYP2C19 inhibitor; Omeprazole AUC 280% voriconazole is recommended.
CYP2C19 and CYP3A4 Voriconazole Cmax 15%
substrate] Voriconazole AUC 41% When initiating voriconazole in
patients already receiving
Other proton pump inhibitors omeprazole doses of 40 mg or
that are CYP2C19 substrates above, it is recommended that
may also be inhibited by the omeprazole dose be halved.
voriconazole and may result in
increased plasma concentrations
of these medicinal products.
Ranitidine (150 mg BID) Voriconazole Cmax and AUC ↔ No dose adjustment
[increases gastric pH]
Antiarrhythmics
Digoxin (0.25 mg QD) Digoxin Cmax ↔ No dose adjustment
[P-gp substrate] Digoxin AUC ↔
Quinidine Although not studied, increased Contraindicated (see section
[CYP3A4 substrate] plasma concentrations of quinidine 4.3)
can lead to QTc prolongation and
rare occurrences of torsades de
pointes.
Antibacterials
Flucloxacillin Significantly decreased plasma If concomitant administration of
[CYP450 inducer] voriconazole concentrations have voriconazole with flucloxacillin
been reported. cannot be avoided, monitor for
potential loss of voriconazole
effectiveness (e.g., by therapeutic
drug monitoring); increasing the
dose of voriconazole may be
needed.
Macrolide antibiotics No dose adjustment
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 534b27e000563107a8bd6c73d67131e3dbf51bbeeb2ec364adce0f84e9ccd348 · Zeichen 2117–4967 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 74
HOS-109598 · Präparat HOS-093201
Medicinal product Interaction Recommendations concerning
geometric mean changes (%) coadministration
Antacids
Cimetidine (400 mg BID) Voriconazole Cmax 18% No dose adjustment
[non-specific CYP450 inhibitor Voriconazole AUC 23%
and increases gastric pH]
Omeprazole (40 mg QD)* Omeprazole Cmax 116% No dose adjustment of
[CYP2C19 inhibitor; Omeprazole AUC 280% voriconazole is recommended.
CYP2C19 and CYP3A4 Voriconazole Cmax 15%
substrate] Voriconazole AUC 41% When initiating voriconazole in
patients already receiving
Other proton pump inhibitors omeprazole doses of 40 mg or
that are CYP2C19 substrates above, it is recommended that
may also be inhibited by the omeprazole dose be halved.
voriconazole and may result in
increased plasma concentrations
of these medicinal products.
Ranitidine (150 mg BID) Voriconazole Cmax and AUC ↔ No dose adjustment
[increases gastric pH]
Antiarrhythmics
Digoxin (0.25 mg QD) Digoxin Cmax ↔ No dose adjustment
[P-gp substrate] Digoxin AUC ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) digoxin (HOS-086172) ranitidine (HOS-085660) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage bebd80b17ebeb6e13bb01acb51cf5fdac5c0fd4d76d9ee1c6a71e499a8005c19 · Zeichen 2057–3647 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 62.5 mg film-coated tablets Tracleer 125 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-109942 · Präparat HOS-093279
Digoxin: Co-administration for 7 days of bosentan 500 mg twice daily with digoxin decreased the
AUC, Cmax and Cmin of digoxin by 12%, 9% and 23%, respectively. The mechanism for this interaction
may be induction of P-glycoprotein. This interaction is unlikely to be of clinical relevance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage 00d2dd9c69bbb565c8ce12bf614b54f258a33a8ed0363e7366fad0d598c40355 · Zeichen 9149–9437 im Abschnitt
Wechselwirkungen · Tracleer
Tracleer 32 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 33
HOS-109991 · Präparat HOS-093279
Digoxin: Co-administration for 7 days of bosentan 500 mg twice daily with digoxin decreased the
AUC, Cmax and Cmin of digoxin by 12%, 9% and 23%, respectively. The mechanism for this interaction
may be induction of P-glycoprotein. This interaction is unlikely to be of clinical relevance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage 00d2dd9c69bbb565c8ce12bf614b54f258a33a8ed0363e7366fad0d598c40355 · Zeichen 9093–9381 im Abschnitt
Wechselwirkungen · Arixtra
Arixtra 1.5 mg/0.3 ml solution for injection, pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 6
HOS-110100 · Präparat HOS-093307
Oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and
digoxin did not interact with the pharmacokinetics of fondaparinux. The fondaparinux dose (10 mg) in
the interaction studies was higher than the dose recommended for the present indications.
Fondaparinux neither influenced the INR activity of warfarin, nor the bleeding time under
acetylsalicylic acid or piroxicam treatment, nor the pharmacokinetics of digoxin at steady state.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): piroxicam (HOS-110101) digoxin (HOS-086172) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage 1627f4b2b004d5f54ad0bb330a8fad4c900e455e8528487492497dee87af842a · Zeichen 147–624 im Abschnitt
Wechselwirkungen · Arixtra
Arixtra 2.5 mg/0.5 ml solution for injection, pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 19
HOS-110118 · Präparat HOS-093307
Oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and
digoxin did not interact with the pharmacokinetics of fondaparinux. The fondaparinux dose (10 mg) in
the interaction studies was higher than the dose recommended for the present indications.
Fondaparinux neither influenced the INR activity of warfarin, nor the bleeding time under
acetylsalicylic acid or piroxicam treatment, nor the pharmacokinetics of digoxin at steady state.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): piroxicam (HOS-110101) digoxin (HOS-086172) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage 1627f4b2b004d5f54ad0bb330a8fad4c900e455e8528487492497dee87af842a · Zeichen 147–624 im Abschnitt
Wechselwirkungen · Arixtra
Arixtra 5 mg/0.4 ml solution for injection, pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 32–33
HOS-110142 · Präparat HOS-093307
32
Platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin did not interact with the
pharmacokinetics of fondaparinux. At the 10 mg dose used in the interaction studies, fondaparinux did
not influence the bleeding time under acetylsalicylic acid or piroxicam treatment, nor the
pharmacokinetics of digoxin at steady state.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): piroxicam (HOS-110101) digoxin (HOS-086172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage 4c4201890135682cce0c3bae9516f780fc5b79c9ad6265c9b6ce74063a505077 · Zeichen 484–826 im Abschnitt
Wechselwirkungen · Arixtra
Arixtra 7.5 mg/0.6 ml solution for injection, pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 44–45
HOS-110166 · Präparat HOS-093307
44
Platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin did not interact with the
pharmacokinetics of fondaparinux. At the 10 mg dose used in the interaction studies, fondaparinux did
not influence the bleeding time under acetylsalicylic acid or piroxicam treatment, nor the
pharmacokinetics of digoxin at steady state.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): piroxicam (HOS-110101) digoxin (HOS-086172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage 93000ed312c3ad29d1a38a9dab04de194f6cdac3491791244b5c5ce86c2f8eab · Zeichen 484–826 im Abschnitt
Wechselwirkungen · Arixtra
Arixtra 10 mg/0.8 ml solution for injection, pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 56
HOS-110190 · Präparat HOS-093307
Platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin did not interact with the
pharmacokinetics of fondaparinux. At the 10 mg dose used in the interaction studies, fondaparinux did
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): piroxicam (HOS-110101) digoxin (HOS-086172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage ac732789a4e42130376cbb4a77cd43478c6fa16a0431cea1cebe61596b3afe7e · Zeichen 429–631 im Abschnitt
Wechselwirkungen · Arixtra
Arixtra 10 mg/0.8 ml solution for injection, pre-filled syringe. · Abschnitt 4.5 · PDF-Seite 56–57
HOS-110191 · Präparat HOS-093307
56
not influence the bleeding time under acetylsalicylic acid or piroxicam treatment, nor the
pharmacokinetics of digoxin at steady state.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): piroxicam (HOS-110101) digoxin (HOS-086172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T11:30:00Z · SHA-256 381af76ffd2bbb8fff8013d6d98ed50ab7a9f4fb8da38de9af66e45dcfd01fac · Passage a6bbea71b6e91c82de0852e012ca4f436684b54b58f8672f44587babf8903607 · Zeichen 686–825 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 40 mg/12.5 mg tablets MicardisPlus 80 mg/12.5 mg tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-110380 · Präparat HOS-093371
7
Digoxin
When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma
concentration (49%) and in trough concentration (20%) were observed. When initiating, adjusting, and
discontinuing telmisartan, monitor digoxin levels in order to maintain levels within the therapeutic
range.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 36a1f81648cc84a3013b1f19574ca3bcda1f385d44106ab495e44f2faa7c6305 · Zeichen 3009–3319 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 80 mg/25 mg tablets · Abschnitt 4.5 · PDF-Seite 27
HOS-110436 · Präparat HOS-093371
Digoxin
When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma
concentration (49%) and in trough concentration (20%) were observed. When initiating, adjusting, and
discontinuing telmisartan, monitor digoxin levels in order to maintain levels within the therapeutic
range.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 06a6f039c1c43b56f3991f7d6258a2fbb400649594d9911f9df739500e3379f2 · Zeichen 2957–3264 im Abschnitt
Wechselwirkungen · Forsteo
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 4
HOS-111023 · Präparat HOS-093433
In a study of 15 healthy subjects administered digoxin daily to steady state, a single FORSTEO dose
did not alter the cardiac effect of digoxin. However, sporadic case reports have suggested that
hypercalcaemia may predispose patients to digitalis toxicity. Because FORSTEO transiently increases
serum calcium, FORSTEO should be used with caution in patients taking digitalis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:20:00Z · SHA-256 1571e886a5969a7f43ca0235f8b0a587a54392572741cea41fd72e7028e88f2e · Passage e255e8940d635da9276c3cc25a0f74878d9c45a5f9b5669e14302c0adb27af5b · Zeichen 0–376 im Abschnitt
Wechselwirkungen · Ventavis
Ventavis 10 microgram/ml nebuliser solution Ventavis 20 microgram/ml nebuliser solution · Abschnitt 4.5 · PDF-Seite 8
HOS-111559 · Präparat HOS-093549
Intravenous infusion of iloprost has no effect either on the pharmacokinetics of multiple oral doses of
digoxin or on the pharmacokinetics of co-administered tissue plasminogen activator (t-PA) in patients.
Although, clinical studies have not been conducted, in vitro studies investigating the inhibitory
potential of iloprost on the activity of cytochrome P450 enzymes revealed that no relevant inhibition
of drug metabolism via these enzymes by iloprost is to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): plasminogen (HOS-111560) digoxin (HOS-086172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-31T14:00:00Z · SHA-256 5d47ed2259ef5bba769bbe7ea3d0dcd7a97f55cbf461ed2c9672f6d6834b03fd · Passage f6ed8104bd811b897e29ed7838f49707cee7546071adc119b014915c875aa70f · Zeichen 1297–1771 im Abschnitt
Wechselwirkungen · Levitra
Levitra 5 mg film-coated tablets Levitra10 mg film-coated tablets Levitra 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111593 · Präparat HOS-093557
The pharmacokinetics of vardenafil (20 mg) was not affected by co-administration with the
H2-antagonist ranitidine (150 mg twice daily), digoxin, warfarin, glibenclamide, alcohol (mean
maximum blood alcohol level of 73 mg/dl) or single doses of antacid (magnesium hydroxide/aluminium
hydroxide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) magnesium hydroxide (HOS-088789) ranitidine (HOS-085660) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage 6f0a217c442baffdacfacf0514818389f6b11731320df1d843d044e033189782 · Zeichen 2799–3094 im Abschnitt
Wechselwirkungen · Levitra
Levitra 5 mg film-coated tablets Levitra10 mg film-coated tablets Levitra 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-111606 · Präparat HOS-093557
No significant interactions were shown when warfarin (25 mg), which is metabolised by CYP2C9, or
digoxin (0.375 mg) was co-administered with vardenafil (20 mg film-coated tablets). The relative
bioavailability of glibenclamide (3.5 mg) was not affected when co-administered with vardenafil
(20 mg). In a specific study, where vardenafil (20 mg) was co-administered with slow release nifedipine
(30 mg or 60 mg) in hypertensive patients, there was an additional reduction on supine systolic blood
pressure of 6 mmHg and supine diastolic blood pressure of 5 mmHg accompanied with an increase in
heart rate of 4 bpm.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) digoxin (HOS-086172) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage 213a4ece6b46d6e4d8baeef821261b054f0bfc9e68e29e582b736d88f1c90c97 · Zeichen 6831–7444 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.